Therapeutic doses of doxorubicin induce premature senescence of human mesenchymal stem cells derived from menstrual blood, bone marrow and adipose tissue.

摘要: Doxorubicin (Dox) is an effective anticancer drug with known activity against a wide spectrum of malignancies, hematologic malignancies in particular. Despite extensive clinical use, the mechanisms its side effects and negative action on normal cells remain under study. The aim this study was to investigate effect Dox cultured human mesenchymal stem (MSCs) derived from menstrual blood (eMSCs), bone marrow (BMSCs) adipose tissue (AMSCs). treatment high doses decreased survival MSCs dose-dependent manner. Clinically relevant low induced premature senescence eMSCs, BMSCs AMSCs, but did not kill cells. caused cell cycle arrest formation γ-H2AX foci, increased number SA-β-gal-positive entered earlier than other MSCs. It has been reported that neural-like differentiated various origins are more sensitive their parent Dox-treated exhibited lower viability generation foci. administration inhibited secretory These findings suggest clinically dose damages MSCs, inducing senescence. resistant damage